- Home
- CRNX
as of 11-28-2025 12:37pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.1B | IPO Year: | 2018 |
| Target Price: | $71.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.10 - $60.34 | Next Earning Date: | 11-06-2025 |
| Revenue: | $1,535,000 | Revenue Growth: | 47.74% |
| Revenue Growth (this year): | 405.68% | Revenue Growth (next year): | 1034.87% |
AI-Powered CRNX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
Chief Med and Dev Officer
Avg Cost/Share
$42.96
Shares
5,000
Total Value
$213,312.00
Owned After
66,370
Chief Med and Dev Officer
Avg Cost/Share
$41.81
Shares
5,000
Total Value
$209,050.00
Owned After
66,370
SEC Form 4
President & CEO
Avg Cost/Share
$45.00
Shares
4,000
Total Value
$180,000.00
Owned After
106,000
SEC Form 4
Director
Avg Cost/Share
$44.75
Shares
16,000
Total Value
$716,000.00
Owned After
22,836
SEC Form 4
Chief Med and Dev Officer
Avg Cost/Share
$32.10
Shares
5,000
Total Value
$160,500.00
Owned After
66,370
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Nov 3, 2025 | Sell | $42.96 | 5,000 | $213,312.00 | 66,370 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Oct 1, 2025 | Sell | $41.81 | 5,000 | $209,050.00 | 66,370 | |
| Struthers Richard Scott | CRNX | President & CEO | Sep 26, 2025 | Sell | $45.00 | 4,000 | $180,000.00 | 106,000 | |
| Fust Matthew K | CRNX | Director | Sep 26, 2025 | Sell | $44.75 | 16,000 | $716,000.00 | 22,836 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Sep 2, 2025 | Sell | $32.10 | 5,000 | $160,500.00 | 66,370 |
Compare CRNX vs Leading Stocks
See how CRNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.